Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
15.05
-0.14 (-0.92%)
Jun 16, 2026, 4:00 PM EDT - Market closed
Amylyx Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 229.14 | 226.65 | 77.39 | 170.2 | 62.53 | 50.19 |
Short-Term Investments | 50.63 | 90.33 | 99.11 | 201.16 | 284.42 | 45.93 |
Cash & Short-Term Investments | 279.77 | 316.98 | 176.5 | 371.36 | 346.95 | 96.12 |
Cash Growth | 37.09% | 79.59% | -52.47% | 7.04% | 260.96% | 646.43% |
Accounts Receivable | - | 0.09 | 0.45 | 40.05 | 15.31 | - |
Inventory | - | - | - | 38.32 | 9.77 | - |
Other Current Assets | 5.26 | 6.6 | 12.48 | 14.93 | 10.11 | 8.83 |
Total Current Assets | 285.02 | 323.67 | 189.43 | 464.67 | 382.13 | 104.95 |
Net Property, Plant & Equipment | 5.09 | 5.49 | 2.73 | 6.41 | 8.14 | 0.47 |
Other Long-Term Assets | 3.49 | 3.48 | 1.47 | 46.38 | 1.19 | 0.19 |
Total Assets | 293.6 | 332.65 | 193.63 | 517.45 | 391.45 | 105.61 |
Accounts Payable | 3.53 | 3.52 | 2.94 | 22.06 | 6.26 | 4.37 |
Accrued Expenses | 11.28 | 17.91 | 23.95 | 57.72 | 38.31 | 13.02 |
Current Portion of Leases | 1.16 | 1.26 | 1.52 | 2.26 | 2.04 | - |
Total Current Liabilities | 15.97 | 22.69 | 28.41 | 82.04 | 46.61 | 17.4 |
Long-Term Leases | 4.48 | 4.7 | 0.46 | 1.98 | 4.24 | - |
Other Long-Term Liabilities | - | - | - | - | - | 0.04 |
Total Long-Term Liabilities | 4.48 | 4.7 | 0.46 | 1.98 | 4.24 | 0.04 |
Total Liabilities | 20.44 | 27.39 | 28.87 | 84.02 | 50.85 | 17.43 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 |
Additional Paid-in Capital | 1,066 | 1,056 | 771.54 | 738.18 | 694.91 | 4.67 |
Accumulated Other Comprehensive Income | 0.24 | 0.4 | -0.09 | 0.2 | -0.09 | 0.01 |
Retained Earnings | -792.71 | -751.43 | -606.69 | -304.95 | -354.22 | -155.85 |
Total Common Shareholders' Equity | 273.16 | 305.26 | 164.77 | 433.43 | 340.61 | -151.17 |
Minority Interest | - | - | - | - | - | 239.35 |
Shareholders' Equity | 273.16 | 305.26 | 164.77 | 433.43 | 340.61 | 88.18 |
Total Liabilities & Equity | 293.6 | 332.65 | 193.63 | 517.45 | 391.45 | 105.61 |
Total Debt | 5.63 | 5.96 | 1.98 | 4.24 | 6.28 | 0 |
Net Cash (Debt) | 274.14 | 311.02 | 174.52 | 367.13 | 340.67 | 96.12 |
Net Cash Growth | -11.86% | 78.22% | -52.46% | 7.77% | 254.43% | 662.00% |
Net Cash Per Share | 2.72 | 3.29 | 2.56 | 5.25 | 5.82 | 14.59 |
Book Value | 273.16 | 305.26 | 164.77 | 433.43 | 340.61 | -151.17 |
Book Value Per Share | 2.71 | 3.23 | 2.42 | 6.19 | 5.82 | -22.95 |
Tangible Book Value | 273.16 | 305.26 | 164.77 | 433.43 | 340.61 | -151.17 |
Tangible Book Value Per Share | 2.71 | 3.23 | 2.42 | 6.19 | 5.82 | -22.95 |